Nav1.7-IN-2 is primarily used in research and development focused on pain management and neurological disorders. It acts as a selective inhibitor of the Nav1.7 sodium channel, which is implicated in the transmission of pain signals. By blocking this channel, it has the potential to reduce pain sensations without affecting other sensory or motor functions. This makes it a promising candidate for developing novel analgesics, particularly for chronic pain conditions that are resistant to conventional treatments. Additionally, it is being studied for its potential in treating certain types of neuropathic pain and inherited erythromelalgia, a condition characterized by severe burning pain. Its application in preclinical studies helps in understanding the role of Nav1.7 in pain pathways and in identifying new therapeutic strategies.